Testing out the vaccine on juvenile barramundi.
UVAXX
Barramundi Group and the leader in autogenous vaccines in aquaculture and animal health UVAXX, together with Singapore's A*STAR Infectious Diseases Labs - ID Labs, have developed a novel epitope-based vaccine that defends against the Scale Drop Disease Virus (SDDV) infection in Asian sea bass, barramundi.
According to a statement released by the Singapore-based company, this vaccine will be a potential "game-changer" for the Asian sea bass aquaculture sector, as SDDV has inflicted severe losses on farmers.
"We are grateful for the visionary leadership of Professor Laurent Renia, A*STAR Senior Fellow (ID Labs), and support from the Singapore Food Agency and National Research Foundation Singapore to enable the success of this project," the statement reads.
According to the Group, epitope-based vaccine technology is novel in fish health applications and can be adapted to counter emerging viruses in other fish species.
"We look forward to UVAXX and A*STAR identifying more use cases of this technology and developing vaccine solutions that help farmers reduce stock losses and the use of antimicrobials," it ends.
On the other hand, Barramundi Group announced a month ago that its Brunei subsidiary had awarded AquaBioTech Group a turnkey contract for the design, supply, installation, and commissioning of a state-of-the-art RAS (Recirculating Aquaculture System) broodstock, hatchery and live feed facility for barramundi in Brunei Darussalam.
UVAXX, the company specializing in autogenous vaccines and fish health, is at the forefront of autogenous vaccine development for barramundi and other tropical fish species. Its unique position as a provider of these vaccines in Southeast Asia has garnered significant interest and opportunities.